

VPA10454/058/001

GastroGard 370 mg/g oral paste

Variation	Summary	Date
Vet - B3 t)	VNRA - Vet - B3 t) - - Vet - B3 t) - Changes to the quality part of the dossier: Deletion of a Ph. Eur. CEP — for an active substance;— for a starting material, reagent or intermediate used in the manufacturing process of the active substance;— for an excipient	25/07/25
Vet - B47 c)	VNRA - Vet - B47 c) - c) Change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur. - B47 c) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change in specifications from a national pharmacopoeia of a Member State to the Ph. Eur.	09/06/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	28/03/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	07/07/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	07/07/23
Vet - A1 a)	VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administrative changes: Change in the name or address or contact details of the marketing authorisation holder	29/03/23
Vet - A1 a)	VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administrative	15/12/22

	changes: Change in the name or address or contact details of the marketing authorisation holder	
Vet - A1 e)	VNRA - Vet - A1 e) - e) Change in the name or address or contact details of a manufacturer or importer of the finished product (including batch release or quality control testing sites) - A1 e) Administrative changes: Change in the name or address or contact details of a manufacturer or importer of the finished product (including batch release or quality control testing sites)	08/08/22
Vet - A1 a)	VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administrative changes: Change in the name or address or contact details of the marketing authorisation holder	08/08/22